定量动态增强MRI诊断肝脏局灶性病变价值研究*

doi:10.3969/j.issn.1672-5069.2025.05.034

Abstract

Abstract: Objective The aim of this study was to investigate diagnostic performance of quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)in patients with focal liver lesions (FLL). Methods 103 consecutive patients with FLL were encountered in Second People's Hospital, Lianyungang, Jiangsu Province between February 2022 and July 2024, and all of them underwent DCE-MRI scan and had had histology-proven diagnosis. Quantitative parameters of DCE-MRI , e.g., volume transfer constant (Ktrans), reverse rate constant (Kep)and extracellular volume fraction (Ve) were recorded, and receiver operating characteristic (ROC) curveswere applied to evaluate diagnostic efficacy of DCE-MRI scan. Results Of 103 patients with FLL in our series, histo-pathological examination made diagnosis of hepatocellular carcinoma(HCC)in 64 cases, intrahepatic cholangiocarcinoma (ICC) in 12 cases, focal nodular hyperplasia (FNH) in 8 cases and hepatic hemangioma (HH) in 19 cases; proportions of lesions with rich blood supply at arterial phase of DCE-MRI in HCC group and in HH group were 90.6% and 100.0%, both much higher than 41.7% in ICC group or 75.0% in FNH group (P＜0.05); Ktrans, Kep and Ve in HH were (0.4±0.1),(0.5±0.1) and (0.7±0.2), and were (0.3±0.1),(0.4±0.1) and (0.5±0.1) in FNH, all significantly lower than [(0.7±0.2),(0.9±0.3) and (1.1±0.4), respectively, P＜0.05] in HCC or [(0.6±0.2),(0.8±0.3) and (1.0±0.3), respectively, P＜0.05] in ICC; sensitivity, specificity and accuracy by DCE-MRI in diagnosing HCC were 93.8%, 92.3% and 93.2%, in diagnosing ICC were 83.3%, 95.6%and 94.2%, in diagnosing FNH were 75.0%, 97.9%and 96.1%, and in diagnosing HH were 89.5%, 98.8% and 97.1%, very promising consistency with histo-pathological diagnosis (all kappa>0.7). Conclusion Quantitative DCE-MRI scan has a high diagnostic efficacy in evaluating intrahepatic FLL, which might help clinicians make an appropriate medical intervention choice.

Key words: Focal liver lesion, Hepatoma, Dynamic contrast-enhanced magnetic resonance imaging, Quantitative parameters, Diagnosis

Liu Jingfang, Zhang Subo, Ding Junming, et al. Diagnostic performance of quantitative dynamic contrast-enhanced magnetic resonance imaging in patients with focal liver lesions[J]. Journal of Practical Hepatology, 2025, 28(5): 776-779.

References

[1] Wei Y, Yang M, Zhang M, et al. Focal liver lesion diagnosis with deep learning and multistage CT imaging. Nat Commun,2024,15(1):7040-7043.
[2] Stollmayer R, Budai BK, Rónaszéki A, et al. Focal liver lesion MRI feature identification using efficient net and MONAI: a feasibility study. Cells,2022,11(9):1558-1560.
[3] Ma L, Wang L, Khatib SA, et al. Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Hepatol,2021, 75(6):1397-1408.
[4] Li W, Li R, Zhao X, et al. Differentiation of hepatocellular carcinoma from hepatic hemangioma and focal nodular hyperplasia using computed tomographic spectral imaging. J Clin Transl Hepatol,2021,9(3):315-323.
[5] Mejia JC, Pasko J. Primary liver cancers: intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Surg Clin North Am,2020,100(3):535-549.
[6] Sun Y, Zhu Q, Huang M, et al. Liver DCE-MRI registration based on sparse recovery of contrast agent curves. Med Phys,2021,48(11):6916-6929.
[7] 谢晶美,刘浩,李安,等.动态增强MRI定量参数术前评估原发性肝癌患者临床分期研究.实用肝脏病杂志,2024,27(2):255-258.
[8] Chen BB, Lin ZZ, Shao YY, et al. Early changes in DCE-MRI biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: two prospective phase II trials. Cancers (Basel),2021,13(19):4962-4965.
[9] Gao L, Wang W, Meng X, et al. TPA: Two-stage progressive attention segmentation framework for hepatocellular carcinoma on multi-modality MRI. Med Phys,2024,51(7): 4936-4947.
[10] Kaissis GA, Lohöfer FK, Hörl M, et al. Combined DCE-MRI- and FDG-PET enable histopathological grading prediction in a rat model of hepatocellular carcinoma. Eur J Radiol,2020,5(124):1084-1088.
[11] Alareer HSN, Jasim H, Dinar A. Dynamic contrast enhanced-MRI and apparent diffusion coefficient quantitation for differentiate hepatocellular carcinoma from hepatocellular adenoma. Asian Pac J Cancer Prev,2024,25(3):931-937.
[12] 丹巴玉珍,程盼.增强MRI检查诊断HCC价值研究.实用肝脏病杂志,2024,27(6): 911-914.
[13] Yang J, Dong X, Jin S, et al. Radiomics model of dynamic contrast-enhanced MRI for evaluating vessels encapsulating tumor clusters and microvascular invasion in hepatocellular carcinoma. Acad Radiol,2024,7(17):1076-1078.
[14] 曾旺,蔡晓曼,葛尚.肝内胆管细胞癌与肝细胞癌病灶MRI增强扫描表现差异分析.实用肝脏病杂志,2024,27(6):907-910.
[15] Song Q, Guo Y, Yao X, et al. Comparative study of evaluating the microcirculatory function status of primary small HCC between the CE (DCE-MRI) and non-CE (IVIM-DWI) MR perfusion imaging. Abdom Radiol,2021,46(6):2575-2583.
[16] Dong X, Yang J, Zhang B, et al. Deep learning radiomics model of dynamic contrast-enhanced MRI for evaluating vessels encapsulating tumor clusters and prognosis in hepatocellular carcinoma. J Magn Reson Imaging,2024,59(1):108-119.
[17] Zhou Y, Zhou G, Zhang J, et al. DCE-MRI based radiomics nomogram for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma. Eur Radiol,2022,32(7):5004-5015.
[18] Barzegar M, Taghiloo A, Abedi R. Editorial for "the early-enhancing hepatic vein: differentiating focal nodular hyperplasia and hepatic adenoma with pathologic validation in MRI". J Magn Reson Imaging,2023,58(4):1198-1199.
[19] Kania LM, Dave J, Guglielmo FF, et al. The early-enhancing hepatic vein: differentiating focal nodular hyperplasia and hepatic adenoma with pathologic validation in MRI. J Magn Reson Imaging,2023,58(4):1191-1197.
[20] Brancato V, Garbino N, Salvatore M, et al. MRI-based radiomic features help identify lesions and predict histopathological grade of hepatocellular carcinoma. Diagnostics,2022,12(5): 1085-1088.
[21] 贾素兰,卢昊宁,杜静波.肝脏小血管瘤患者MRI动态增强和弥散成像表现特征.实用肝脏病杂志,2024,27(1):113-116.
[22] Liu Z, Yi L, Chen J, et al. Comparison of the clinical and MRI features of patients with hepatic hemangioma, epithelioid hemangioendothelioma, or angiosarcoma. BMC Med Imaging,2020,20(1):71-75.

Diagnostic performance of quantitative dynamic contrast-enhanced magnetic resonance imaging in patients with focal liver lesions

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association; Nutrition and Regeneration in End-Stage Liver Disease Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the diagnosis and treatment of acute-on-chronic liver failure (2025 version) [J]. Journal of Practical Hepatology, 2025, 28(5): 641-647.
[2]	Tang Jie, Jiang Zhengwei, Zhou Bingqing, et al. Diagnostic performance of shear wave elastography combined with APRI and FIB-4 in predicting liver fibrosis in patients with serum HBeAg positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2025, 28(5): 663-666.
[3]	Wang Lingyun, Mei Ying, Chen Mengxue, et al. Diagnostic efficacy of non-alcoholic fatty liver diseases by quantitative CT measurement in individuals for physical examination [J]. Journal of Practical Hepatology, 2025, 28(5): 687-690.
[4]	Cheng Zhonghua, Tang Nan, Gu Shuo, et al. Serum miR-122, miR-140-5p and miR-34a levels in patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(5): 695-698.
[5]	Ge Tianming, Wu Qiyuan, Yu Xiaowei, et al. Verification of magnetic resonance imaging proton density fat fraction in predicting liver steatosis in patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(5): 703-706.
[6]	Wang Chuang, Zhou Lin, Gao Huanhuan, et al. Predictive performance of thromboelastogram parameters and blood coagulation indexes for portal vein thrombosis in patients with liver cirrhosis after splenectomy [J]. Journal of Practical Hepatology, 2025, 28(5): 739-742.
[7]	Li Jialiang, Duan Yan, Shen Jian, et al. Diagnosis of cirrhotic cardiomyopathy in patients with hepatitis B-induced liver cirrhosis by Doppler tissue imaging and echocardiography [J]. Journal of Practical Hepatology, 2025, 28(5): 743-746.
[8]	Li Xin, Mei Wenjuan, Zhang Haoyue. Contrast-enhanced ultrasonography and enhanced CT/MRI LI-RADS classification in the diagnosis of small hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2025, 28(5): 755-758.
[9]	Zhang Xiaozhao, Lei Kai, Qi Yabin, et al. Attilizumab and targeting and immune checkpoint inhibitor combination after TACE in the treatment of patients with advanced primary liver cancer [J]. Journal of Practical Hepatology, 2025, 28(5): 759-762.
[10]	Xu Jia, Peng Weiwei, Yin Na, et al. Clinical observation of sintilimab and anti-vascular endothelial growth factor antibody in the treatment of patients with unresectable hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2025, 28(5): 763-766.
[11]	Ye Qin, Ye Li, Luo Xin, et al. Serum alpha-fetoprotein levels and multilayer spiral CT parameters in assessing benign and malignant liver nodules [J]. Journal of Practical Hepatology, 2025, 28(5): 767-770.
[12]	Wang Jiahui, Cui Liming. TACE in combination with lenvatinib and sintilimab in the treatment of patients with beyondup-to-seven criteria hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2025, 28(5): 771-775.
[13]	Song Xiaoyu, Chen Ning, Gao Feng, et al. Etiological feature and prognosis of children with non-hepatophilic viral infection with liver injury [J]. Journal of Practical Hepatology, 2025, 28(4): 525-528.
[14]	Ni Shenjue, Wang Pengfei, Huang Yanhua, et al. Changes of serum maresin-1, omentin-1 and microRNA-125b, and their correlation to liver inflammation and fibrosis in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(4): 533-536.
[15]	Han Yudong, Zhang Je, Zhang Wenjin, et al. Application of ultrasound-derived fat fraction in the diagnosis of metabolic associated fatty liver disease: a preliminary study [J]. Journal of Practical Hepatology, 2025, 28(4): 553-556.